Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 62 entries
Sorted by: Best Match Show Resources per page
Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia.

Human psychopharmacology

Drake CL, Roehrs TA, Mangano RM, Roth T.
PMID: 12404612
Hum Psychopharmacol. 2000 Dec;15(8):595-604. doi: 10.1002/hup.216.

The effects of two nights of treatment with the short-acting benzodiazepine receptor agonist zaleplon, triazolam, or placebo was assessed in chronic primary insomniacs using two concurrent, multi-center, randomized, double-blind, Latin Square crossover studies. Study 1 (n = 47) compared...

Cite
Drake CL, Roehrs TA, Mangano RM, et al. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psychopharmacol. 2000;15(8):595-604doi: 10.1002/hup.216.
Drake, C. L., Roehrs, T. A., Mangano, R. M., & Roth, T. (2000). Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Human psychopharmacology, 15(8), 595-604. https://doi.org/10.1002/hup.216
Drake, Christopher L, et al. "Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia." Human psychopharmacology vol. 15,8 (2000): 595-604. doi: https://doi.org/10.1002/hup.216
Drake CL, Roehrs TA, Mangano RM, Roth T. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psychopharmacol. 2000 Dec;15(8):595-604. doi: 10.1002/hup.216. PMID: 12404612.
Copy Download .nbib Format: NLM
Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task.

Human psychopharmacology

Rush CR, Baker RW.
PMID: 12404585
Hum Psychopharmacol. 2001 Mar;16(2):147-157. doi: 10.1002/hup.240.

Zolpidem (AMBIEN((R))), an imidazopyridine, is now the most commonly prescribed hypnotic in the United States. Zolpidem is neuropharmacologically distinct from benzodiazepine hypnotics in that it binds with low affinity to alpha(5)-containing GABA(A)-receptor subtypes. Despite its unique benzodiazepine-receptor binding profile,...

Cite
Rush CR, Baker RW. Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Hum Psychopharmacol. 2001;16(2):147-157doi: 10.1002/hup.240.
Rush, C. R., & Baker, R. W. (2001). Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Human psychopharmacology, 16(2), 147-157. https://doi.org/10.1002/hup.240
Rush, Craig R., and Baker, Robert W.. "Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task." Human psychopharmacology vol. 16,2 (2001): 147-157. doi: https://doi.org/10.1002/hup.240
Rush CR, Baker RW. Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Hum Psychopharmacol. 2001 Mar;16(2):147-157. doi: 10.1002/hup.240. PMID: 12404585.
Copy Download .nbib Format: NLM
Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys.

Behavioural pharmacology

Auta J, Faust WB, Lambert P, Guidotti A, Costa E, Moerschbaecher JM.
PMID: 11224341
Behav Pharmacol. 1995 Jun;6(4):323-332.

Two baselines involving a repeated acquisition task were used to assess the effects of bretazenil, imidazenil, and triazolam. The first baseline was a multiple schedule of repeated acquisition and performance of conditional discriminations. In the first component, the subject...

Cite
Auta J, Faust WB, Lambert P, et al. Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. Behav Pharmacol. 1995;6(4):323-332
Auta, J., Faust, W. B., Lambert, P., Guidotti, A., Costa, E., & Moerschbaecher, J. M. (1995). Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. Behavioural pharmacology, 6(4), 323-332.
Auta, J., et al. "Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys." Behavioural pharmacology vol. 6,4 (1995): 323-332.
Auta J, Faust WB, Lambert P, Guidotti A, Costa E, Moerschbaecher JM. Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. Behav Pharmacol. 1995 Jun;6(4):323-332. PMID: 11224341.
Copy Download .nbib Format: NLM
Differential illness intrusiveness associated with sleep-promoting medications.

European psychiatry : the journal of the Association of European Psychiatrists

Devins G, Flanigan M, Fleming J, Morehouse R, Moscovitch A, Plamondon J, Reinish L, Shapiro C.
PMID: 19698412
Eur Psychiatry. 1995;10:153s-9s. doi: 10.1016/0924-9338(96)80097-6.

Differences in daytime sleepiness, lifestyle disruptions, and emotional distress were compared across nine groups taking sleep-promoting substances. Groups included individuals taking zopiclone (n = 274), amitriptyline (n = 107), lorazepam (n = 258), oxazepam (n= 141), diphenhydramine HCl (n...

Cite
Devins G, Flanigan M, Fleming J, et al. Differential illness intrusiveness associated with sleep-promoting medications. Eur Psychiatry. 1995;10:153s-9sdoi: 10.1016/0924-9338(96)80097-6.
Devins, G., Flanigan, M., Fleming, J., Morehouse, R., Moscovitch, A., Plamondon, J., Reinish, L., & Shapiro, C. (1995). Differential illness intrusiveness associated with sleep-promoting medications. European psychiatry : the journal of the Association of European Psychiatrists, 10153s-9s. https://doi.org/10.1016/0924-9338(96)80097-6
Devins, G, et al. "Differential illness intrusiveness associated with sleep-promoting medications." European psychiatry : the journal of the Association of European Psychiatrists vol. 10 (1995): 153s-9s. doi: https://doi.org/10.1016/0924-9338(96)80097-6
Devins G, Flanigan M, Fleming J, Morehouse R, Moscovitch A, Plamondon J, Reinish L, Shapiro C. Differential illness intrusiveness associated with sleep-promoting medications. Eur Psychiatry. 1995;10:153s-9s. doi: 10.1016/0924-9338(96)80097-6. PMID: 19698412.
Copy Download .nbib Format: NLM
Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia.

European psychiatry : the journal of the Association of European Psychiatrists

Hajak G, Clarenbach P, Fischer W, Haase W, Bandelow B, Adler L, Rüther E.
PMID: 19698415
Eur Psychiatry. 1995;10:173s-9s. doi: 10.1016/0924-9338(96)80100-3.

The effect of treatment (28 days) with zopiclone, triazolam, flunitrazepam and placebo on sleep quality and daytime well-being was proven in a randomised, double-blind, parallel group, multicentre study in private practice. Results of an exploratory statistic of treatment efficacy...

Cite
Hajak G, Clarenbach P, Fischer W, et al. Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatry. 1995;10:173s-9sdoi: 10.1016/0924-9338(96)80100-3.
Hajak, G., Clarenbach, P., Fischer, W., Haase, W., Bandelow, B., Adler, L., & Rüther, E. (1995). Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. European psychiatry : the journal of the Association of European Psychiatrists, 10173s-9s. https://doi.org/10.1016/0924-9338(96)80100-3
Hajak, G, et al. "Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia." European psychiatry : the journal of the Association of European Psychiatrists vol. 10 (1995): 173s-9s. doi: https://doi.org/10.1016/0924-9338(96)80100-3
Hajak G, Clarenbach P, Fischer W, Haase W, Bandelow B, Adler L, Rüther E. Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatry. 1995;10:173s-9s. doi: 10.1016/0924-9338(96)80100-3. PMID: 19698415.
Copy Download .nbib Format: NLM
A reassessment of triazolam.

The International journal of risk & safety in medicine

Kales A, Vgontzas AN, Bixler EO.
PMID: 23512020
Int J Risk Saf Med. 1996;9(1):7-27. doi: 10.3233/JRS-1996-9102.

Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific...

Cite
Kales A, Vgontzas AN, Bixler EO. A reassessment of triazolam. Int J Risk Saf Med. 1996;9(1):7-27doi: 10.3233/JRS-1996-9102.
Kales, A., Vgontzas, A. N., & Bixler, E. O. (1996). A reassessment of triazolam. The International journal of risk & safety in medicine, 9(1), 7-27. https://doi.org/10.3233/JRS-1996-9102
Kales, A, et al. "A reassessment of triazolam." The International journal of risk & safety in medicine vol. 9,1 (1996): 7-27. doi: https://doi.org/10.3233/JRS-1996-9102
Kales A, Vgontzas AN, Bixler EO. A reassessment of triazolam. Int J Risk Saf Med. 1996;9(1):7-27. doi: 10.3233/JRS-1996-9102. PMID: 23512020.
Copy Download .nbib Format: NLM
Analysis of the effect of oral midazolam and triazolam premedication before general anesthesia in patients with disabilities with difficulty in cooperation.

Journal of dental anesthesia and pain medicine

Lim SW, So E, Yun HJ, Karm MH, Chang J, Lee H, Kim HJ, Seo KS.
PMID: 30186971
J Dent Anesth Pain Med. 2018 Aug;18(4):245-254. doi: 10.17245/jdapm.2018.18.4.245. Epub 2018 Aug 28.

BACKGROUND: When performing dental treatment under general anesthesia in adult patients who have difficulty cooperating due to intellectual disabilities, anesthesia induction may be difficult as well. In particular, patients who refuse to come into the dental office or sit...

Cite
Lim SW, So E, Yun HJ, et al. Analysis of the effect of oral midazolam and triazolam premedication before general anesthesia in patients with disabilities with difficulty in cooperation. J Dent Anesth Pain Med. 2018;18(4):245-254doi: 10.17245/jdapm.2018.18.4.245.
Lim, S. W., So, E., Yun, H. J., Karm, M. H., Chang, J., Lee, H., Kim, H. J., & Seo, K. S. (2018). Analysis of the effect of oral midazolam and triazolam premedication before general anesthesia in patients with disabilities with difficulty in cooperation. Journal of dental anesthesia and pain medicine, 18(4), 245-254. https://doi.org/10.17245/jdapm.2018.18.4.245
Lim, Seon Woo, et al. "Analysis of the effect of oral midazolam and triazolam premedication before general anesthesia in patients with disabilities with difficulty in cooperation." Journal of dental anesthesia and pain medicine vol. 18,4 (2018): 245-254. doi: https://doi.org/10.17245/jdapm.2018.18.4.245
Lim SW, So E, Yun HJ, Karm MH, Chang J, Lee H, Kim HJ, Seo KS. Analysis of the effect of oral midazolam and triazolam premedication before general anesthesia in patients with disabilities with difficulty in cooperation. J Dent Anesth Pain Med. 2018 Aug;18(4):245-254. doi: 10.17245/jdapm.2018.18.4.245. Epub 2018 Aug 28. PMID: 30186971; PMCID: PMC6115375.
Copy Download .nbib Format: NLM
Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report.

Case reports in medicine

Kobayashi N, Yoshimura R, Takano M.
PMID: 22481958
Case Rep Med. 2012;2012:893681. doi: 10.1155/2012/893681. Epub 2012 Mar 14.

Sleep-related eating disorder (SRED) is characterized by recurrent episodes of involuntary eating during sleep period and is often associated with restless legs syndrome (RLS). Although pharmacotherapy is recommended for SRED patients, no drug have shown promising effects so far....

Cite
Kobayashi N, Yoshimura R, Takano M. Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report. Case Rep Med. 2012;2012:893681doi: 10.1155/2012/893681.
Kobayashi, N., Yoshimura, R., & Takano, M. (2012). Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report. Case reports in medicine, 2012893681. https://doi.org/10.1155/2012/893681
Kobayashi, Nobuyuki, et al. "Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report." Case reports in medicine vol. 2012 (2012): 893681. doi: https://doi.org/10.1155/2012/893681
Kobayashi N, Yoshimura R, Takano M. Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report. Case Rep Med. 2012;2012:893681. doi: 10.1155/2012/893681. Epub 2012 Mar 14. PMID: 22481958; PMCID: PMC3312196.
Copy Download .nbib Format: NLM
Preoperative psychogenic fever: to operate or not to operate.

Journal of surgical case reports

Koren SF, Engel LE, Møller MP.
PMID: 33815760
J Surg Case Rep. 2021 Mar 29;2021(3):rjab114. doi: 10.1093/jscr/rjab114. eCollection 2021 Mar.

Postponing elective surgery because of fever on the morning of the operation is frustrating for patients as well as doctors. It is also not cost effective and the unused operation capacity could have been used on other patients. On...

Cite
Koren SF, Engel LE, Møller MP. Preoperative psychogenic fever: to operate or not to operate. J Surg Case Rep. 2021;2021(3):rjab114doi: 10.1093/jscr/rjab114.
Koren, S. F., Engel, L. E., & Møller, M. P. (2021). Preoperative psychogenic fever: to operate or not to operate. Journal of surgical case reports, 2021(3), rjab114. https://doi.org/10.1093/jscr/rjab114
Koren, Sondre F, et al. "Preoperative psychogenic fever: to operate or not to operate." Journal of surgical case reports vol. 2021,3 (2021): rjab114. doi: https://doi.org/10.1093/jscr/rjab114
Koren SF, Engel LE, Møller MP. Preoperative psychogenic fever: to operate or not to operate. J Surg Case Rep. 2021 Mar 29;2021(3):rjab114. doi: 10.1093/jscr/rjab114. eCollection 2021 Mar. PMID: 33815760; PMCID: PMC8007217.
Copy Download .nbib Format: NLM
Prevalence and concentrations of sedative-hypnotic drugs in blood of drivers involved in road traffic crashes in the Padova region of Italy - not so easy to interpret.

Forensic science international

Favretto D, Visentin S, Jones AW.
PMID: 34814082
Forensic Sci Int. 2021 Nov 06;330:111097. doi: 10.1016/j.forsciint.2021.111097. Epub 2021 Nov 06.

BACKGROUND & OBJECTIVES: This study reports the prevalence and concentrations of sedative-hypnotic drugs as exemplified by benzodiazepines (BZD) and zolpidem (Z-hypnotic) in blood samples from drivers involved in road traffic accidents (RTA) in the Padova region of Italy. Another...

Cite
Favretto D, Visentin S, Jones AW. Prevalence and concentrations of sedative-hypnotic drugs in blood of drivers involved in road traffic crashes in the Padova region of Italy - not so easy to interpret. Forensic Sci Int. 2021;330:111097doi: 10.1016/j.forsciint.2021.111097.
Favretto, D., Visentin, S., & Jones, A. W. (2021). Prevalence and concentrations of sedative-hypnotic drugs in blood of drivers involved in road traffic crashes in the Padova region of Italy - not so easy to interpret. Forensic science international, 330111097. https://doi.org/10.1016/j.forsciint.2021.111097
Favretto, Donata, et al. "Prevalence and concentrations of sedative-hypnotic drugs in blood of drivers involved in road traffic crashes in the Padova region of Italy - not so easy to interpret." Forensic science international vol. 330 (2021): 111097. doi: https://doi.org/10.1016/j.forsciint.2021.111097
Favretto D, Visentin S, Jones AW. Prevalence and concentrations of sedative-hypnotic drugs in blood of drivers involved in road traffic crashes in the Padova region of Italy - not so easy to interpret. Forensic Sci Int. 2021 Nov 06;330:111097. doi: 10.1016/j.forsciint.2021.111097. Epub 2021 Nov 06. PMID: 34814082.
Copy Download .nbib Format: NLM
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF.
PMID: 34743790
J Clin Sleep Med. 2021 Sep 01;17(9):1895-1945. doi: 10.5664/jcsm.9326.

INTRODUCTION: This systematic review provides supporting evidence for the accompanying clinical practice guideline on the treatment of central disorders of hypersomnolence in adults and children. The review focuses on prescription medications with U.S. Food & Drug Administration approval and...

Cite
Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895-1945doi: 10.5664/jcsm.9326.
Maski, K., Trotti, L. M., Kotagal, S., Robert Auger, R., Swick, T. J., Rowley, J. A., Hashmi, S. D., & Watson, N. F. (2021). Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 17(9), 1895-1945. https://doi.org/10.5664/jcsm.9326
Maski, Kiran, et al. "Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment." Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine vol. 17,9 (2021): 1895-1945. doi: https://doi.org/10.5664/jcsm.9326
Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021 Sep 01;17(9):1895-1945. doi: 10.5664/jcsm.9326. PMID: 34743790; PMCID: PMC8636345.
Copy Download .nbib Format: NLM
PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Pharmaceutical research

Balhara A, Singh S.
PMID: 34518943
Pharm Res. 2021 Sep;38(9):1485-1496. doi: 10.1007/s11095-021-03095-9. Epub 2021 Sep 13.

PURPOSE: Isoniazid (INH) is prescribed both for the prophylaxis as well as the treatment of tuberculosis. It is primarily metabolized through acetylation by a highly polymorphic enzyme, N-acetyl transferase 2 (NAT2), owing to which significant variable systemic drug levels...

Cite
Balhara A, Singh S. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid. Pharm Res. 2021;38(9):1485-1496doi: 10.1007/s11095-021-03095-9.
Balhara, A., & Singh, S. (2021). PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid. Pharmaceutical research, 38(9), 1485-1496. https://doi.org/10.1007/s11095-021-03095-9
Balhara, Ankit, and Singh, Saranjit. "PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid." Pharmaceutical research vol. 38,9 (2021): 1485-1496. doi: https://doi.org/10.1007/s11095-021-03095-9
Balhara A, Singh S. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid. Pharm Res. 2021 Sep;38(9):1485-1496. doi: 10.1007/s11095-021-03095-9. Epub 2021 Sep 13. PMID: 34518943.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 62 entries